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Objective: Screening for abdominal aortic aneurysms (AAA) significantly reduces aneurysm-related death. In January
2007, the Federal government enacted Medicare coverage guideline to screen persons at risk for the presence of an AAA,
the Screen for Abdominal Aortic Aneurysms Very Efficiently (SAAAVE) Act. The purpose of this study is to evaluate the
efficacy and costs of a large scale screening effort for identifying AAAs in patients in clinical practice.
Methods: A regional veterans affairs mandate for screening for AAA was implemented in February 2007. Data were
extracted through the Northern California Veterans Affairs (VA) Service Network to identify veteran males 65-75 years
of age who ever smoked at least 100 cigarettes during their lifetime. An AAA was defined as an aortic diameter 3.0 cm or
greater. A Decision Support Systems software (LumiData, Minneapolis, Minn) package tracked true costs of conducting
a large AAA screening protocol in the Northern California VA Health Care System.
Results: A total of 2918 patients (average age, 71  6 years) were screened for AAA over a 1-year period from February
2007 to February 2008. An AAAwas diagnosed in 5.1% (148/2918) of patients. Two hundred ninety patients out of the
2918 (9.9%) were inappropriately screened. The aneurysm distribution was as follows: 83% (123/148) of the aneurysms
were 3.0-4.4 cm, 13% (19/148) were 4.5-5.5 cm, and 4.1% (6/148) were greater than 5.5 cm. Incidental findings of
isolated iliac artery aneurysms were found in 0.1% (3/2918) of patients. The cost of AAA screening per patient is $53.
Conclusion: The results of a large AAA screening effort in clinical practice reflect the results reported in the major clinical
trials at a reasonable cost. The identification of large iliac artery aneurysms in the screening has not been previously
reported. (J Vasc Surg 2009;49:1107-11.)Abdominal aortic aneurysms (AAAs) account for over
15,000 deaths in theUnited States each year.1 The aneurysm-
related deaths underestimate the true number of deaths since
patients with ruptured AAAs may never survive the trip to the
hospital to receive medical care. Given the asymptomatic
nature and potentially life-threatening risk, ultrasonography,2
has been proposed as a routine screeningmodality. Its use has
been studied in several randomized prospective studies.3-6
Unanimously, the studies concluded that screening prevented
aneurysm-related death. In 2005, a meta-analysis of these
screening trials prompted the United States Preventive Ser-
vices Task Force (USPSTF) to change its earlier neutral posi-
tion on AAA screening to recommend the screening of all
men between the ages of 65 to 75 who ever smoked 100
cigarettes or more.7
Importantly, the USPSTF cautioned that the limitation
of their recommendations were that none of the studies
were based on patients in the United States. The four
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compared aneurysm-related death rates between a screened
and non-screened patient population. The largest and best
quality study was the UK’s Multicentre Aneurysm Screen-
ing Study (MASS).3 In the United States, no randomized
clinical trial data are available. However, based on spon-
sored screening trials, the Stroke and Aneurysm Vascular
Evaluation (SAVE) program8 demonstrated an AAA prev-
alence of 2.1% and the dare to Carotid artery stenosis,
Abdominal aortic aneurysms, Renal artery stenosis, and
Extremity artery stenosis (CARE) trial9 revealed an AAA
prevalence of 1.6%, significantly lower than the rates re-
ported in the four clinical trials.
Despite the differing prevalence rates reported in the
US and the USPSTF recommendations, several major
medical societies and a bipartisan group of senators and
congressional representatives introduced legislation to en-
able Medicare to cover the costs of AAA screening, the
Screening Abdominal Aortic Aneurysms Very Efficiently
(SAAAVE) act. The act became law in January 1, 2007.
Medicare covers a one-time ultrasound scan screening of
men aged 65-75 who ever smoked in their lifetime or men
andwomenwho have a family history of AAA disease as part
of a “Welcome to Medicare” package. To allow for the
covered ultrasound scan screening, the “Welcome toMedi-
care” physical examination must take place within 6
months that the beneficiary becomes eligible. In essence,
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ficiaries before 2007 and potentially many future Medicare
beneficiaries who fail to meet the strict Welcome to Medi-
care guidelines.
The Department of Veterans Affairs (VA) adopted a
more expansive view of the AAA screening program. Rather
than exclude patients who are already in the VA system, as
the SAAAVE act excludes all patients already inMedicare, a
retroactive screening protocol was enacted. Approximately
one million veteran patients meet criteria and will be
screened. To institute the screening program to all eligible
patients, the VA mandates that all practitioners remain
judicious in working down the patient backlog. The pur-
pose of this study is to evaluate 1-year results of the efficacy
and associated costs in implementing a large AAA screening
effort and to identify the prevalence of patients with AAAs
in the context of a US clinical practice.
METHODS
An initial evaluation was made of male veterans 65-75
who smoked or female patients older than 50 with a family
history of AAA who had utilized the VA health care system
from the previous fiscal year, 2006. This drew from a large
database of patients in the Northern California VA Health
Care System. Patient lists were generated and notices were
sent to veterans by the radiology department as an invita-
tion for AAA screening. Simultaneously, through the elec-
tronic medical records system, alerts were posted to the
primary care physicians that an AAA screening was due for
their patient. Implementation of the VA-mandated screen-
ing protocol began January 1, 2007, in response to the new
federal law, the SAAAVE act. A 1-month period was re-
quired to develop and implement a unique CPT code for
“AAA screening” in the VA system. This code was utilized
beginning February 1, 2007, to track utilization and asso-
ciated costs. All patients who underwent AAA screening
from February 2007 to February 2008 with this CPT code
were identified.
A retrospective review of all patients having been
screened for an AAA during this time period was conducted
under an Investigational Review Board (IRB) approved
protocol at the Northern California VA Health Care Sys-
tem. Age, aortic diameter, and costs associated with the
screening protocol were evaluated. Identification of an
AAA was defined as an aortic diameter measuring 3.0 cm or
larger. Prevalence and cost data were compared to a prior
large-scale screening trial, the MASS.3 MASS was selected
for comparison because of the “good quality” rating in the
USPSTF recommendations as well as MASS had the nar-
rowest confidence interval and contributed the most
weight to the pooled odds ratio in the USPSTF recommen-
dations.7
Cost data regarding the implementation of the AAA
screening protocol was tracked prospectively using the VA
Decision Support Systems.10,11 The Decision Support Sys-
tems is a computer software program where the budgetallocation system combines clinical and fiscal information at
a detailed level. This VA budget allocation system was
piloted in 1986 and began full implementation at the
behest of Congress in 1994.11 The Northern California VA
Health Care Systems has an independent department
which tracks these costs so that budgetary planning can be
made for successive years.
Since the VA does not generate a bill, direct costs such
as the technician, administrative support, and radiologists’
time are not calculated on a per patient basis. Rather, all
costs in running the radiology department, for example, are
estimated. The budget department then requests an esti-
mate of the proportion effort devoted to the screening
program. This value is then divided by the number of
patients screened in that particular time period. Other large
expense items such as the ultrasound machine, gurneys,
probes, and software packages are not included in the cost
estimate to implement the screening program since the VA
already owns these items and no incremental costs were
required.
Continuous variables are reported as a mean  stan-
dard deviation. A two-tailed t test was employed to com-
pare continuous variables, and a 2 test was utilized to
compare proportions. A P value of less than .05 was con-
sidered statistically significant.
RESULTS
Over the 1-year period, 2918 patients (average 71  6
years) were successfully screened for AAA. A total of 84%
(2918/3487) eligible veterans were screened. A total of
9.9% (290/2918) were inappropriately screened: 118 pa-
tients were under 65-years-old, 172 patients were over
75-years-old, and 7 women were screened without a clear
family history of aneurysmal disease. All 7 women were also
too old to be included in the screening. Only 0.3% (9/
2918) of patients had a non-diagnostic ultrasound scan
screening requiring a non-contrast abdominal/pelvic com-
puted tomography (CT) scan for screening. The age distri-
bution and the percent screened were not statistically dif-
ferent in this study when compared to the results obtained
in the MASS trial. The age was 71  6 in this VA study
compared to the MASS trial of 69.2  3 years (P  NS).
The percent screened was 84% (2918/3487) in this VA
study, whereas the MASS study screened 80% (27,147/
33,839) (P .11). A comparison of age and the percentage
of patients screened are reported in Table I.
A total of 5.1% (148/2918) were diagnosed with an
AAA 3.0 cm or larger, this result is similar to that reported
in the MASS trial at 4.9% (1333/26,818) of patients in-
vited (P  .82). The screened patients were mostly men
99.8% (2911/2918), 59.7% (1743/2918) White, 10.8%
(314/2918) African American, 3.8% (112/2918) Asian/
Pacific Islander, and 25.2% (736/2918) unknown. The
distributions of the aneurysm diameter in the patients
identified with an AAA were: 83% (123/148) for the
3.0-4.4 cm group, 13% (19/148) for the 4.5-5.4 cm, and
4.1% (6/148) for the 5.5 cm or greater group. The distri-
bution of AAA diameters compare similarly to that of the
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the MASS trial reported a 12% rate (166/1333) (P 
.006). The distribution of aneurysm prevalence and aneu-
rysm distribution are summarized and compared with three
other randomized controlled screening trials in Table II.
The Chichester study was excluded from the table because
of the differing diameter criteria reported and the use of 6.0
cm threshold for surgical intervention.
Out of the total number of patients screened, there
were 0.4% (12/2918) of patients who had an AAA 5.0 cm
or larger. Isolated iliac artery aneurysms were found in 0.1%
(3/2918) of patients. All 22 patients with a 3.0 cm iliac
artery aneurysm or an AAA greater than 4.5 cm in size were
appropriately referred to the vascular surgery service.12
An analysis of the cost data was based on the proportion
of labor (administrative support, radiologists, and techni-
cians) devoted to the screening in addition to supplies and
other indirect costs. Weighted averages of costs estimate
were calculated from the following Northern California VA
Medical Centers: Martinez, Sacramento, Redding, and
Oakland. In 2008, the estimated cost per screening was
$53. To keep the dollar cost analysis in terms of 2008
dollars, the cost analysis was based on a data capture from
January 1, 2008, to September 1, 2008, different than the
time period for the evaluation of the screening protocol.
Costs can differ based upon the number of radiologists on
staff, the volume of studies performed, the cost of living in
that geographical area, and the less tangible estimates of
indirect costs, such as the amortized costs of the equipment
and overhead. Based on cost data collected through Deci-
sions Support Systems, the screening costs were $1050 to
identify a patient with an AAA at least 3.0 cm in diameter,
$6200 for an AAA at least 4.5 cm in diameter, and $25,900
for an AAA at least 5.5 cm in diameter. The escalating costs
are due to the decreasing prevalence of larger aneurysms in
the patient population. The costs reflect an estimate of what
would be required to identify an aneurysm at each respec-






VA study 70.5  6 65-75 84%
2918/3487
MASS (2002) 69.2  3 65-74 80%
27,147/33,839
Danish (2002) 67.5* 65-73 76%
4843/6339
Australian (2004) 72.6  5 65-83 63%
12,203/19,352
No significant differences identified in the ages between studies. Only the
Australian study reported a lower attendance rate in the invitation for
screening.
No standard deviation (SD) is reported for the Danish study. VA, Veterans
Affairs; MASS, Multicentre Aneurysm Screening Study.tive diameter.DISCUSSION
In January 1, 2007, the SAAAVE act became law. A
payment will be made for a one-time screening of patients
for identifying an AAA who meet the following criteria:13
(1) Complete an initial preventive physical examination
(Welcome to Medicare Visit) within 6 months of Medicare
eligibility, (2) Have not previously had an ultrasound scan
screening examination under the Medicare program, and
(3) Be a man aged 65-75 years of age who smoked at least
100 cigarettes or be a man or woman who has a family
history of AAA.
Thus, the eligibility for Medicare covered AAA screen-
ing is rather limited.
The Northern California VA Health Care System has
worked aggressively to apply the VA directive. An analysis
of the past year’s efforts have been presented here and
compared to the benchmarks set by the USPSTF best
evidence reviews.7 Within the Task Force’s evaluation of
the data, theMASS3 results were heavily weighted account-
ing for 60.2% of the patients evaluated. Further sub-analysis
excluding the MASS results by the Task Force led to the
same conclusions, that screening prevented aneurysm-re-
lated death. In our analysis, the MASS results were used as
the benchmark with which to compare the efficacy of the
Northern California VA screening results in actual practice
(Table I). A limitation of the Task Force recommendations
was the applicability of European and Australian publica-
tions to aUS population. This retrospective study is the first
to evaluate the clinical application of a screening protocol in
a large US clinical practice. The results reported in this
study are more closely aligned to the data reported in the
other large clinical trials as opposed to the initiated screen-
ing trials performed in the United States.8,9 The design of
the US studies were to offer a free ultrasound scan screen-
ing to eligible patients typically in shopping malls. The
prevalence may be lower in these studies as healthier sub-
jects in the invited screening would be more likely to
participate than as part of a screening protocol in clinical
care. The prevalence rate in these studies ranged from 1.6%
to 2.1%, significantly lower than the 5% reported in this
study and the other randomized clinical trials.
There are some practical challenges in assessing the
results of the screening efforts. Patients in clinical practice
will move in and out of eligibility based on geographic,
insurance, and age concerns. Depending upon the time the
eligibility assessment is made, a patient may be age eligible
at the time of data capture (ie, 75-years-old) but be 76-
years-old at the time the ultrasound scan examination is
completed. The capture rate of 84% screened vs eligible
patients, compares favorably with the 80% screening rate
obtained in the MASS study. The 9.9% rate of inappropri-
ately screened patients is likely due to primary care physi-
cians incorrectly ordering an AAA screening examination.
In the VA system, meeting clinical reminders are rewarded,
where as inappropriate ordering of studies are not necessar-
ily punished. The improved yield rate will likely reflect a
ASS
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clinical practice.
An ultrasound scan was usually technically adequate for
screening. Only 0.3% of examinations were unable to mea-
sure aortic diameters, compared to the 1.2% screening
failure reported in the MASS trial. The reason for this is
unclear.Whether the VA radiologists were willing to render
an interpretation of aortic diameter based on limited views
compared to the more extensive visualization demanded by
the MASS study design is speculation. Another possibility
is the hands-on approach of the VA radiologists working
with the technologists to obtain an adequate study.
The identification of isolated iliac artery aneurysms
requiring treatment occurred in 0.1% of patients, whereas
no mention of incidental iliac artery aneurysms were made
in the MASS trial3 or the USPSTF review.7 This observa-
tion supports the importance of vascular laboratory techni-
cians to evaluate the iliac arteries.
The data reported here showed a significantly lower
prevalence of large aneurysms of 5.5 cm or greater at 4.1%
of patients compared to the 12% of patients reported in the
MASS trial. This difference could be attributed to a couple
of factors. The VA included patients who are utilizing their
health care benefits and it is possible that their risk factors
may be more effectively managed. The MASS trial subjects
were culled from a population-based group of patients who
were not necessarily utilizing their health care benefits.
Secondly, the incident rate of active smokers in our VA
patients at the time of screening in a post-hoc analysis was
25%. Whether this rate of active smokers compares favor-
ably to the MASS trial is unknown. A smaller fraction of
active smokers in the aneurysmal population could argue
for the effect of aneurysm expansion rate and the prevalence
of larger aneurysms.
This study evaluated costs, not charges or reimburse-
ment. The VA does not bill Medicare for screening studies.
The VA has a Decision Support System for analysis of
expenditures and associated indirect costs for services. In
the analysis of cost, the VA does not generate a bill as does
the private sector. The Decision Support System methods
for cost analysis have been published elsewhere.10,11 The
average cost per patient is $53. Reported here are slightly
Table II. Comparison of AAAs detected and diameters be
Inconclusive AAA detected
VA study 0.3% 5.1%
9/2,918 148/2,918
MASS study 1.2% 4.9%
329/27,147 1,333/26,818




*P value .0001 NS
*Comparisons are made between the VA data and the data reported in the M
distribution of aneurysms. AAA, Abdominal aortic aneurysms; VA, Veteranlower than prior estimates generated by Wanhainen et al14who estimated the costs to be $55 per screening study for
patients over 65 years of age in 2003 dollars.
In the analysis of recommending a screening program,
the cost to administer the study is an important variable.
Costs of screening will decrease and quality should improve
with greater volumes. Based on this analysis, a more expan-
sive application of the SAAAVE act for Medicare beneficia-
ries should be considered. The SAAAVE act excludes mil-
lions of Medicare beneficiaries who enrolled prior to 2007
and new beneficiaries who fail to meet fairly strict guide-
lines: complete a Welcome to Medicare physical within 6
months of enrolling and have an AAA ultrasound scan
screening performed. This further detracts from the utility
of the screening efforts since many primary care physicians
will not routinely think AAA screening.
The important aspect of this screening is not limited to
identifying patients with large aneurysms (greater than 5.5
cm) for repair, but rather the identification of patients with
smaller aneurysms of 4.0-5.4 cm. Several aneurysm trials
have shown the natural history of patients with small aneu-
rysms to require repair 60% of the time in a 3-year follow-up
period.15,16 Given this strategy, further ultrasound scan
studies will be required in this subset of patients for follow-
up. Wanhainen et al have already included this possibility in
their Markov analysis model. They conclude that a mass
AAA screening protocol is still cost-effective.14 A careful
analysis of costs and outcome of patients with a 3.0-4.5
AAA diameter will need to be followed prospectively.
Although no US randomized clinical trial was per-
formed comparing AAA screening to a control population
without screening, several salient points should be consid-
ered from these large randomized controlled trials. From
the MASS study, screened patients with a 4.5 cm or larger
AAA that were detected in a study population (1%) had a
significant 42% relative risk reduction in aneurysm related
deaths. The US population may have a greater risk reduc-
tion since the spread between elective AAA repair mortality
rates are 3.1%17 and emergent AAA repair mortality rates
are 44%.18 In the MASS UK dataset, there was a 7%
perioperative mortality for elective AAA repair and a 37%
mortality for ruptured AAA repair. This is important since












study. The Danish study used different aneurysm diameters to describe the
irs; MASS, Multicentre Aneurysm Screening Study.tweeruptured aneurysms.
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reports a reduction from 3% in the unscreened group to 2%
in the screened group. Although the all-cause mortality was
not significantly reduced, there was a significant reduction
in ischemic heart disease deaths signifying a secondary
benefit to screening. Furthermore, through a screening
program, an additional 2.5 patients would have an AAA
detected for every AAA detected through routine care. This
estimate is extrapolated from the 92 large aneurysms (5.5
cm) detected through routine care as opposed to 322
aneurysms detected through a screening program in the
MASS study. Given that over 15,000 elective repairs were
performed in US Medicare beneficiaries annually, a more
expansive screening program could potentially generate an
additional 37,500 Medicare patients that have an AAA
5.5 cm.
CONCLUSIONS
The clinical application of a large AAA screening pro-
gram, compare well with the results of several randomized
controlled screening studies. Isolated iliac artery aneurysms
greater than 3.0 cm have been identified, demonstrating
the importance of the ultrasonographer to screening the
iliac arteries. Serious consideration should be given to
expanding the SAAAVE act for Medicare beneficiaries to a
retrospective expanded screening effort, similar to that
enjoyed by our veteran patients.
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